Siriraj Medical Journal (Sep 2016)

The Association of MTHFR C677T and A1298C Polymorphisms with Methotrexate Response and Toxicity in Psoriasis

  • Sauvarat Auepemkiate,
  • Anothai Pocathikorn,
  • Pornprot Limprasert,
  • Paramee Thongsuksai,
  • Kanokphorn Chiratikarnwong,
  • Thavatchai Chuaprapaisilp,
  • Sunisa Thaichinda,
  • Panadda Konandana

DOI
https://doi.org/10.14456/smj.2016.11
Journal volume & issue
Vol. 68, no. 5
pp. 271 – 276

Abstract

Read online

Background: Methotrexate (MTX) is used to treat psoriasis with various side effects and responsiveness. No predictive indicator of responsivenessor toxicityis available. Objective: Tostudytheassociationof the C677T and A1298C polymorphisms inthe methylenetetrahydrofolate reductase (MTHFR) gene withthe responsiveness andside effectsof MTX in psoriatic Thai patients. Methods: Thepolymorphisms wereidentifiedfrom86MTX-treatedpatientsinthreehospitalslocatedinsouthern Thailandusing allele-specificPCR. Thepatients were monitored for the effectiveness and toxicity of the MTX. Results: The C677T genotype frequencies for C/C, C/T, and T/T were 70.9, 26.8, and 2.3%, respectively, and those of the A1298C genotypes for A/A, A/C, and C/C were 57, 32.5, and 10.5%, respectively. Seventy-three patients (87.9%) respondedtoMTX. Thenon-respondershadhighercombinedfrequenciesof C/T and T/T of the C677T (50%) thanthe responders (24.7%) withnostatistical significance (p=0.131),buthada lower frequency of CC genotypeof the A1298C, althoughnot statisticallydifferent (p=0.691). Elevenpatients (12.8%) suffered toxicity. No association of thesepolymorphisms and MTX toxicity was found. Conclusion: The studydidnot show anassociationbetweenthese MTHFR polymorphisms with MTX response and toxicityin thesepatients.

Keywords